Raymond James & Associates Acadia Pharmaceuticals Inc Transaction History

Raymond James & Associates

  • $146 Billion
  • Q1 2024

A detailed history of Raymond James & Associates transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Raymond James & Associates holds 12,809 shares of ACAD stock, worth $209,042. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,809
Holding current value
$209,042
% of portfolio
0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 22, 2024
BUY
$17.79 - $30.86 $227,872 - $395,285
12,809 New
12,809 $236,000
Q3 2023

Oct 24, 2023
BUY
$20.84 - $33.47 $33,969 - $54,556
1,630 Added 18.14%
10,614 $221,000
Q2 2023

Jul 25, 2023
BUY
$17.8 - $25.65 $159,915 - $230,439
8,984 New
8,984 $215,000
Q1 2021

May 14, 2021
SELL
$25.02 - $54.99 $784,927 - $1.73 Million
-31,372 Closed
0 $0
Q4 2020

Feb 12, 2021
BUY
$41.04 - $56.79 $1.29 Million - $1.78 Million
31,372 New
31,372 $1.68 Million
Q3 2020

Nov 04, 2020
SELL
$36.42 - $57.0 $621,798 - $973,161
-17,073 Closed
0 $0
Q2 2020

Jul 28, 2020
SELL
$39.26 - $52.73 $90,572 - $121,648
-2,307 Reduced 11.9%
17,073 $828,000
Q1 2020

Apr 21, 2020
SELL
$31.65 - $46.87 $75,643 - $112,019
-2,390 Reduced 10.98%
19,380 $819,000
Q4 2019

Feb 12, 2020
BUY
$36.21 - $51.4 $277,803 - $394,340
7,672 Added 54.42%
21,770 $931,000
Q3 2019

Nov 07, 2019
SELL
$22.22 - $44.01 $14,065 - $27,858
-633 Reduced 4.3%
14,098 $507,000
Q2 2019

Aug 06, 2019
BUY
$23.32 - $28.12 $343,526 - $414,235
14,731 New
14,731 $394,000

Others Institutions Holding ACAD

# of Institutions
298
Shares Held
158M
Call Options Held
1.88M
Put Options Held
688K
View Full List

About ACADIA PHARMACEUTICALS INC

ACAD Quotes by TradingView
  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.64B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email